Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2016, Article ID 6131608, 6 pages
http://dx.doi.org/10.1155/2016/6131608
Research Article

Ingestibility and Formulation Quality of Lansoprazole Orally Disintegrating Tablets

1Division of Pharmaceutics, Hokkaido Pharmaceutical University School of Pharmacy, Hokkaido, Japan
2Keihan Hospital, Osaka, Japan

Received 14 July 2016; Accepted 31 October 2016

Academic Editor: Anthony A. Attama

Copyright © 2016 Sumio Chono et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The Ministry of Health, Labour, and Welfare, Ministerial Notification No. 65: The Japanese Pharmacopoeia, Orally Disintegrating Tablets/Orodispersible Tablets, 16th edition, 2011.
  2. T. Chiba, Y. Nagasawa, and T. Tairabune, “Investigation of dispensing of naftopidil orally disintegrating tablet (Flivas OD Tablets) using an automatic tablet packing machine,” Japanese Journal of Medicine and Pharmaceutical Science, vol. 59, no. 1, pp. 79–85, 2008. View at Google Scholar
  3. K. Amano, A. Seko, M. Takagi et al., “Clinical efficacy of lansoprazole for patients with gastric and peptic ulcer contained eradication of Helicobacter Pylori,” Japanese Journal of Medicine and Pharmaceutical Science, vol. 39, no. 2, pp. 305–314, 1998. View at Google Scholar
  4. A. Maeda, Y. Tanaka, H. Ishiguro et al., “Clinical efficacy of lansoprazole in treatment of gastric ulcer lnduced by NSAIDs,” Therapeutic Research, vol. 19, no. 5, pp. 1649–1655, 1998. View at Google Scholar
  5. S. Sakamoto, T. lwamoto, and K. lwasaki, “Assessment of effectiveness and safety of lansoprazole on non-erosive reflux disease,” Journal of New Remedies Clinics, vol. 59, no. 8, pp. 1332–1343, 2010. View at Google Scholar
  6. T. Tabata, “Formulation development using enteric coated granules—evolution from capsules to oral disintegrating tablets,” Pharm Tech Japan, vol. 24, no. 1, pp. 157–162, 2008. View at Google Scholar
  7. Nihon Generic Co., Ltd., Medical supplies interview form, Lansoprazole OD Tablets 15 mg “JG”, 2015.
  8. Daiko Pharmaceutical Co, Medical Supplies Interview Form, Lansoprazole OD Tablets 15 mg “DK”, 2015.
  9. Teva Pharma Japan Inc, Medical Supplies Interview Form, Lansoprazole OD Tablets 15 mg “Teva”, 2015.
  10. Towa Pharmaceutical Co, Medical Supplies Interview Form, Lansoprazole OD Tablets 15 mg “TOWA”, 2016.
  11. Nichi-Iko Pharmaceutical Co., Ltd., Medical supplies interview form, Lansoprazole OD Tablets 15 mg “Nichi-Iko”, 2016.
  12. S. Chono, M. Nakagawa, M. Matsui et al., “Clinical evaluation of formulation quality and ingestibility of tamsulosin hydrochloride orally disintegrating tablets 0.1 mg,” Japanese Journal of Generic Medicine, vol. 10, no. 1, pp. 27–34, 2016. View at Google Scholar
  13. K. Hori, N. Yoshida, T. Okumura, Y. Okamura, and J. Kawakami, “Method for the evaluation of the stability and usability after opening packages of orally disintegrating tablets: case of amlodipine besilate products,” Yakugaku Zasshi, vol. 130, no. 8, pp. 1029–1040, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. The Ministry of Health, The Japanese Pharmacopoeia Sixteenth Edition, Disintegration Test, Labour and Welfare Ministerial Notification no. 65, 2011.
  15. The Ministry of Health, Labour and Welfare Ministerial Notification No. 65. The Japanese Pharmacopoeia, Dissolution Tes, 16th edition, 2011.
  16. A. C. Zettlemoyer, “Immersional wetting of solid surfaces,” Industrial & Engineering Chemistry, vol. 57, no. 2, pp. 26–36, 1965. View at Publisher · View at Google Scholar
  17. Y. Masuda, “The current and formulation design of fast oral-disintegrating tablets,” Pharm Tech Japan, vol. 22, pp. 401–412, 2006. View at Google Scholar
  18. C. N. Linda, “Aging, oral health and salivary flow,” Japanese Journal of Gerodontology, vol. 18, no. 2, pp. 107–116, 2003. View at Google Scholar
  19. N. Aoyagi, N. Kaniwa, Y. Takeda, and M. Uchiyama, “Basic concept and rules of dissolution tests in Japanese pharmacopoeia,” Pharmaceutical Regulatory Science, vol. 24, no. 10, pp. 1031–1041, 1993. View at Google Scholar